# A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

> **NCT00434356** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** sunitinib
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00434356
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Based on data collected, the combination appeared to be poorly tolearated.
- **Last updated:** 2009-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434356, "A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00434356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*